CoChat

Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial

Open access
Basolo, Alessio, Burkholder, Joshua, Osgood, Kristy, Graham, Alexis, Bundrick, Sarah, Frankl, Joseph, Piaggi, Paolo, Thearle, Marie S., Krakoff, Jonathan · 2018 · Metabolism
Cited by 43

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Aims Exenatide is a glucagon-like peptide 1 (GLP-1) mimetic which induces weight loss predominantly, it is presumed, via decreased food intake. However, circulating GLP-1 is also a determinant of energy expenditure. We sought to quantify the effect of exenatide on energy expenditure (EE) and energy intake. Materials and Methods In this single-center, randomized double-blind placebo controlled trial, we randomized 80 healthy, non-diabetic volunteers with obesity (46 women, age: 34.4±8.7 y, body fat by DXA: 44.2±7.8%) to subcutaneous exenatide 10 μg twice daily or placebo. Subjects were admitted to our clinical research unit for measurement of 24h-EE in a whole-room indirect calorimeter and ad libitum food intake using an automated vending machine paradigm before and after randomization. Furthermore, energy expenditure and ad libitum food intake measures were repeated at 24-week after readmission for 7-day inpatient stay. Body weight was obtained weekly for up to 5 weeks and was recorded at each monthly follow up visit up to 24 weeks. Results Prior to randomization, participants over ate during the 3-day vending machine period in the whole study group (114.6±35.2 %), expressed as percentage of weight maintaining energy needs (WMEN) with those who were eventually randomized to exenatide overeating more (121.6±37.7 %) compared to placebo group (107.6±31.5 %). In the exenatide group, ad libitum absolute energy intake decreased by 1016.1±724.5 kcal/day (95% CI: −1250.9 to −781.2) versus a 245.1±710.5 kcal/day (95% CI: −475.4 to −14.7) decrease in placebo (Δ= −624.8 Kcal/day, p < .0001) whereas the reduction in ad libitum caloric intake relative to WMEN was a more modest 366.8±752.1 kcal/day (95% CI: −614.0 to −119.6) decrease compared to 8.0±860.1 kcal/day (95% CI: −286.8 to 270.8) reduction in placebo (Δ= −382.3 Kcal/day, p = 0.03). The decrease was uniform across all macronutrients groups. No differences in 24hEE or substrate oxidation rates were found. In the exenatide group, body weight decreased more over the 5 weeks (β = −0.039 kg/week, p = 0.02) and was lower compared to placebo at the end of fifth week (−1.48±0.77 kg; 95% CI: −3.02 to 0.05, p = 0.06). At the 24-week follow up, there was no difference in energy intake between exenatide group and placebo group and the treatment group decreased 24-h EE more compared to placebo (β = −160.6 Kcal/day, 95% CI: −307.6 to 13.6, p = 0.03) compared to their pre-randomization measurement. However, this reduction was not present after adjustment for changes in FM and FFM (β = −87 kcal/day, p = 0.14). No difference was observed in body weight (Δ = −1.72 kg, 95% CI: −5.77 to 2.30, p = 0.39) in exenatide versus placebo over 24 weeks. Conclusion Compared with placebo, exenatide decreased early ad libitum energy intake but did not change 24h-EE. However, the reduction was more modest in relative versus absolute terms (i.e. below that needed for WMEN). Thus, although rate of weight change was greater in the exenatide treated subjects at 5 weeks, the absolute difference in weight was not significant. These findings indicate that although exenatide reduces food intake, it may be more beneficial in blunting overeating and thus may serve to more prevent weight regain following initial weight loss. Clinical Trial Registration Numbers NCT00856609; clinicaltrials.gov

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.metabol.2018.03.017

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 27

  1. Monami, 2009, Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials, Eur J Endocrinol, 160, 909, 10.1530/EJE-09-0101 · DOI · Paper page
  2. Buse, 2007, Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials, Clin Ther, 29, 139, 10.1016/j.clinthera.2007.01.015 · DOI · Paper page
  3. Nelson, 2007, The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes, Diabetes Technol Ther, 9, 317, 10.1089/dia.2006.0024 · DOI · Paper page
  4. Dushay, 2012, Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes, Diabetes Care, 35, 4, 10.2337/dc11-0931 · DOI · Paper page
  5. Pannacciulli, 2006, Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans, Am J Clin Nutr, 84, 556, 10.1093/ajcn/84.3.556 · DOI
  6. Shalev, 1997, Effects of glucagon-like peptide 1 (7–36 amide) on whole-body protein metabolism in healthy man, Eur J Clin Invest, 27, 10, 10.1046/j.1365-2362.1997.540613.x · DOI
  7. Hwa, 1998, Differential effects of intracerebroventricular glucagon-like peptide-1 on feeding and energy expenditure regulation, Peptides, 19, 869, 10.1016/S0196-9781(98)00033-3 · DOI
  8. Flint, 2000, The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans, Int J Obes Relat Metab Disord, 24, 288, 10.1038/sj.ijo.0801126 · DOI
  9. Sun, 2015, Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis, J Diabetes Res, 2015, 10.1155/2015/157201 · DOI · Paper page
  10. Abbott, 1988, Short-term energy balance: relationship with protein, carbohydrate, and fat balances, Am J Physiol Endocrinol Metab, 255, E332, 10.1152/ajpendo.1988.255.3.E332 · DOI · Paper page
  11. Amori, 2007, Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis, JAMA, 298, 194, 10.1001/jama.298.2.194 · DOI · Paper page
  12. Thearle, 2013, Extent and determinants of thermogenic responses to 24 hours of fasting, energy balance, and five different overfeeding diets in humans, J Clin Endocrinol Metab, 98, 2791, 10.1210/jc.2013-1289 · DOI
  13. Pannacciulli, 2007, The 24-h carbohydrate oxidation rate in a human respiratory chamber predicts ad libitum food intake, Am J Clin Nutr, 86, 625, 10.1093/ajcn/86.3.625 · DOI · Paper page
  14. Piaggi, 2013, Lower "awake and fed thermogenesis" predicts future weight gain in subjects with abdominal adiposity, Diabetes, 62, 4043, 10.2337/db13-0785 · DOI
  15. Rising, 1992, Food intake measured by an automated food-selection system: relationship to energy expenditure, Am J Clin Nutr, 55, 343, 10.1093/ajcn/55.2.343 · DOI
  16. Geiselman, 1998, Reliability and validity of a macronutrient self-selection paradigm and a food preference questionnaire, Physiol Behav, 63, 919, 10.1016/S0031-9384(97)00542-8 · DOI
  17. Venti, 2010, Reproducibility of ad libitum energy intake with the use of a computerized vending machine system, Am J Clin Nutr, 91, 343, 10.3945/ajcn.2009.28315 · DOI
  18. Drab, 2016, Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a clinical update of safety and efficacy, Curr Diabetes Rev, 12, 403, 10.2174/1573399812666151223093841 · DOI · Paper page
  19. Edwards, 2001, Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers, Am J Physiol Endocrinol Metab, 281, E155, 10.1152/ajpendo.2001.281.1.E155 · DOI · Paper page
  20. Verdich, 2001, A meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humans, J Clin Endocrinol Metab, 86, 4382
  21. Pinelli, 2011, Effect of administration time of exenatide on satiety responses, blood glucose, and adverse events in healthy volunteers, J Clin Pharmacol, 51, 165, 10.1177/0091270010367653 · DOI
  22. Flint, 2013, The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment, Diabetes Obes Metab, 15, 958, 10.1111/dom.12108 · DOI · Paper page
  23. Madsbad, 2016, Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists, Diabetes, Obesity and Metabolism, 18, 317, 10.1111/dom.12596 · DOI · Paper page
  24. Deane, 2010, Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia, J Clin Endocrinol Metab, 95, 215, 10.1210/jc.2009-1503 · DOI · Paper page
  25. Drucker, 1988, Glucagon gene expression in vertebrate brain, J Biol Chem, 263, 13475, 10.1016/S0021-9258(18)68261-4 · DOI · Paper page
  26. de Fonseca, 2000, Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats, Metabolism, 49, 709, 10.1053/meta.2000.6251 · DOI
  27. Holmes, 2009, Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions, J Physiol, 587, 4749, 10.1113/jphysiol.2009.175067 · DOI

Cited by

See all 43

Metadata

Authors
Basolo, A., Burkholder, J., Osgood, K., Graham, A., Bundrick, S., Frankl, J., Piaggi, P., Thearle, M. S., & Krakoff, J.
Venue
Metabolism
Publisher
Elsevier BV
Published
2018-08
Volume
85
Pages
116-125
ISSN
0026-0495 (ISSN-L)
OpenAlex
W2790926033
Cited by
43
References
17
FWCI
1.49
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/j.metabol.2018.03.017
The paper
Basolo, A., Burkholder, J., Osgood, K., Graham, A., Bundrick, S., Frankl, J., Piaggi, P., Thearle, M. S., & Krakoff, J. (2018). Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial. Metabolism. https://doi.org/10.1016/j.metabol.2018.03.017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.